TMCnet News

Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015 - Research and Markets
[February 03, 2016]

Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015 - Research and Markets


Research and Markets (http://www.researchandmarkets.com/research/lbxsh2/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:



  1. Introduction
  2. Moderate Psoriasis Overview
  3. Therapeutics Development
  4. Pipeline Products for Moderate Psoriasis - Overview
  5. Pipeline Products for Moderate Psoriasis - Comparative Analysis
  6. Moderate Psoriasis - Therapeutics under Development by Companies
  7. Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes
  8. Moderate Psoriasis - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Moderate Psoriasis - Products under Development by Companies
  13. Moderate Psoriasis - Products under Investigation by Universities/Institutes
  14. Moderate Psoriasis - Companies Involved in Therapeutics Development
  • AbGenomics International, Inc.
  • ADC (News - Alert) Therapeutics Sarl
  • Almirall, S.A.
  • AstraZeneca Plc
  • Avexxin AS
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Convoy Therapeutics, Inc.
  • Crescendo Biologics Limited
  • Delenex Therapeutics AG
  • Eli Lilly and Company
  • Forward Pharma A/S
  • Galectin Therapeutics, Inc.
  • GlycoMar Limited
  • Idera Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • OPKO Health, Inc.
  • Sandoz International GmbH
  • Soligenix, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • Syntrix Biosystems, Inc.
  • Valeant Pharmaceuticals International, Inc.

For more information visit http://www.researchandmarkets.com/research/lbxsh2/moderate



[ Back To TMCnet.com's Homepage ]